Toxicologic and pharmacologic properties of iocetamic acid, a new oral cholecystographic agent
Centraal Instituut voor Voedingsonderzoek TNO
de Groot, A.P.
Studies in rats on iocetamic acid show that the LD50 levels of this compound compare favorably with those of a number of other oral cholecystographic agents. Pathologic effects are not found in rats and cats in studies of the subacute toxicity. Incompatibility with an anesthetic or a tranquilizer is not found. The elimination pattern of iocetamic acid in rats and human subjects is different. In rats intestinal excretion is dominating; in human subjects 62% of the dose administered is eliminated in the urine within the first 48 hours. The proportion of iodine recovered from the bile collected in 9 postcholecystectomy patients with biliary fistulas within the first 14 hours after oral administration of iocetamic acid averages 32.3% of the amount of iodine administered; this is enough for good or excellent radiographic findings. No significant changes in the functions of kidney, liver, circulation, or bone marrow are observed in patients after oral administration of routine doses of iocetamic acid. Only the total bilirubin content of plasma increases signficantly within 14 hours; this is a common symptom in oral cholecystography which disappears within 1 week after the administration. © 1969. Chemicals/CAS: bilirubin, 18422-02-1, 635-65-4; chlorpromazine, 50-53-3, 69-09-0; iodine, 7553-56-2; iodobenzene, 591-50-4; iopanoic acid, 96-83-3; iopodic acid, 5587-89-3; Bilirubin, 635-65-4; Butyrates; Chlorpromazine, 50-53-3; Contrast Media; Iodine, 7553-56-2; Iodobenzenes; Iopanoic Acid, 96-83-3; Ipodate, 5587-89-3
To reference this document use:
Toxicology and Applied Pharmacology, 14 (14), 232-241